Quest Diagnostics (DGX) has raised its full-year 2026 guidance, now projecting adjusted diluted EPS between $10.63 and $10.83, up from a previous range of $10.50 to $10.70. The company also increased its net revenue expectations to between $11.78 billion and $11.90 billion, compared to the prior outlook of $11.70 billion to $11.82 billion. In Q1, Quest reported earnings of $252 million, or $2.24 per share, a notable increase from $220 million, or $1.94 per share, year-over-year.
This upward revision in guidance reflects strong performance, with Q1 revenue climbing 9.1% to $2.89 billion. The positive earnings report has translated into a 2.39% increase in pre-market trading, pushing shares to $201.00. Such robust results may signal resilience in the healthcare sector, particularly in diagnostics, amid broader economic uncertainties.
For market professionals, the key takeaway is that Quest’s improved earnings outlook could enhance investor confidence in the healthcare sector, potentially driving further interest and investment in similar stocks.
Source: nasdaq.com